Tesamorelin: GHRH Analogue with an Approved Indication

Structure and stabilisation

Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl group attached at the N-terminus. Native GHRH is rapidly inactivated by dipeptidyl peptidase-4, which cleaves the N-terminal dipeptide. The acyl modification protects that site and extends the functional half-life.

Because it acts through the GHRH receptor on pituitary somatotrophs, growth hormone release remains pulsatile and subject to somatostatin feedback. This is a different profile from exogenous growth hormone administration, and it is the pharmacological argument for the class.

The phase 3 programme

Falutz et al. (J Clin Endocrinol Metab, 2010) report a pooled analysis of two multicentre, double-blind, placebo-controlled phase 3 trials with safety extension data, in HIV-infected patients with excess abdominal fat. This is the pivotal evidence.

Spooner and Olin (Ann Pharmacother, 2012) review the compound for HIV-associated lipodystrophy. Grunfeld et al. (Nat Rev Drug Discov, 2011) covers the approval.

The indication is narrow and specific: visceral adipose tissue reduction in a defined patient population. The trials measured that endpoint in that population, and conclusions outside those boundaries are not supported by this evidence.

Recent work

Russo et al. (AIDS, 2024) examine efficacy and safety in people with HIV on integrase inhibitors, which matters because that drug class is itself associated with weight gain and changes the background against which effects are measured.

Ellis et al. (J Infect Dis, 2025) report effects on neurocognitive impairment in persons with HIV and abdominal obesity, extending the endpoint beyond body composition.

Memdouh et al. (Drug Test Anal, 2021) cover detection of synthetic GHRH analogues, reflecting the compound's presence in anti-doping analysis alongside the rest of this class.